Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03212404
Title	Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Checkpoint Therapeutics, Inc.
Indications	non-Hodgkin lymphoma endometrial carcinoma Hodgkin's lymphoma renal pelvis transitional cell carcinoma melanoma renal cell carcinoma lung small cell carcinoma Merkel cell carcinoma peritoneal mesothelioma ureter transitional cell carcinoma colorectal cancer lung non-small cell carcinoma malignant pleural mesothelioma head and neck squamous cell carcinoma transitional cell carcinoma skin squamous cell carcinoma urethra transitional cell carcinoma
Therapies	Cosibelimab
Age Groups:	adult \| senior
Covered Countries	POL \| NZL \| FRA \| ESP \| AUS

Filter rows:

Showing 1 to 48 of 48 entries

Facility	City	State	Zip	Country	Details
Research Site	Wollongong	New South Wales	2500	Australia	Details
Research Site	Benowa	Queensland	4217	Australia	Details
Research Site	Buderim	Queensland	4556	Australia	Details
Research Site	Greenslopes	Queensland	4120	Australia	Details
Research Site	South Brisbane	Queensland	4101	Australia	Details
Research Site	Woolloongabba	Queensland	4102	Australia	Details
Research Site	Box Hill	Victoria	3128	Australia	Details
Research Site	Malvern	Victoria	3144	Australia	Details
Research Site	Besançon		25030	France	Details
Research Site	Bordeaux		33075	France	Details
Research Site	Grenoble		38700	France	Details
Research Site	Lyon		69495	France	Details
Research Site	Nice			France	Details
Research Site	Christchurch		8140	New Zealand	Details
Research Site	Kraków		31-826	Poland	Details
Research Site	Lublin		20064	Poland	Details
Research Site	Poznań		60693	Poland	Details
Research Site	Warsaw		02-781	Poland	Details
Research Site	Łódź		90302	Poland	Details
Research Site	Chelyabinsk		454087	Russian Federation	Details
Research Site	Kazan		420029	Russian Federation	Details
Research Site	Murmansk		183047	Russian Federation	Details
Research Site	Novosibirsk		630108	Russian Federation	Details
Research Site	Omsk		644013	Russian Federation	Details
Research Site	Saint Petersburg		197022	Russian Federation	Details
Research Site	Saint Petersburg		197758	Russian Federation	Details
Research Site	Tyumen		625041	Russian Federation	Details
Research Site	Volgograd		400138	Russian Federation	Details
Research Site	Cape Town		7700	South Africa	Details
Research Site	George		6529	South Africa	Details
Research Site	Port Elizabeth			South Africa	Details
Research Site	Pretoria		0081	South Africa	Details
Research Site	Soweto		2013	South Africa	Details
Research Site	Barcelona			Spain	Details
Research Site	La Laguna		38320	Spain	Details
Research Site	Madrid			Spain	Details
Research Site	Málaga			Spain	Details
Research Site	Pamplona		31008	Spain	Details
Research Site	Sevilla			Spain	Details
Research Site	Valencia			Spain	Details
Research Site	Hat Yai	Songkhla	90110	Thailand	Details
Research Site	Bangkok		10210	Thailand	Details
Research Site	Bangkok		10330	Thailand	Details
Research Site	Chiang Mai		50200	Thailand	Details
Research Site	Khon Kaen		40002	Thailand	Details
Research Site	Chernivtsi		58013	Ukraine	Details
Research Site	Kharkiv		61103	Ukraine	Details
Research Site	Sumy		40022	Ukraine	Details

Showing 1 to 48 of 48 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field